Hepatic Portal Congestion (Non-Cirrhotic, Investigational)
Highly investigational adjunct for non-cirrhotic hepatic congestion; case reports only; cirrhosis and portal hypertension are absolute exclusions.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for hepatic portal congestion. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for systemic portal hypertension is investigational and considered very high-risk.
- ¿Qué evidencia existe?
- Tier C (investigational). No published trials; only theoretical mention. Evidence-based management of portal hypertension and hepatic congestion: treat underlying cirrhosis or hepatic vein obstruction (Budd-Chiari syndrome, congestive hepatopathy from right heart failure), non-selective beta-blockers (propranolol, nadolol) for varices, endoscopic variceal band ligation, TIPS for refractory variceal bleeding or ascites. Leech therapy cannot address systemic portal pressure and risks severe bleeding in patients with varices or coagulopathy.
- Riesgos principales
- Catastrophic bleeding in patients with esophageal or gastric varices (cirrhosis)
- Severe bleeding from coagulopathy in cirrhotic patients
- Bleeding from bite sites for 6 to 24 hours after detachment (markedly prolonged in cirrhosis)
- Worsening of hepatic encephalopathy from gastrointestinal bleeding
- Local skin infection or, rarely, Aeromonas infection (high risk with cirrhosis)
- Allergic reaction to leech saliva (uncommon)
- Delay of beta-blocker, variceal banding, or TIPS evaluation
- Risk of spontaneous bacterial peritonitis if leech bites near ascitic fluid
- Quién no debería considerar esto
- Patients with cirrhosis and esophageal varices (absolute contraindication)
- Patients with thrombocytopenia (platelets <50,000) or INR >1.5 from liver disease
- Patients with ascites (high infection risk)
- Patients with hepatic encephalopathy
- Patients with active or recent gastrointestinal bleeding
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Patients who have not been managed by a hepatologist
- Qué preguntar a su clínico
- Am I being managed by a hepatologist or transplant center?
- Do I have varices on endoscopy, and have I been offered beta-blocker prophylaxis or banding?
- What are my platelet count, INR, and Child-Pugh / MELD score?
- Am I a candidate for TIPS or liver transplantation?
- What evidence specifically supports leech therapy for portal congestion?
- What is the bleeding risk for someone with my coagulation status?
- What is the cost and is it covered by insurance? (typically not covered)
- Cuándo buscar atención urgente
- Vomiting blood or passing black tarry stools (variceal bleeding — emergency)
- Severe abdominal pain with fever (spontaneous bacterial peritonitis)
- New confusion, sleepiness, or asterixis (hepatic encephalopathy)
- Rapid abdominal swelling or new ascites
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
Qué NO significa esto
- This is NOT FDA-cleared for portal hypertension or hepatic congestion.
- Theoretical mention does NOT establish safety or efficacy in cirrhotic patients with varices and coagulopathy.
- Leech therapy CANNOT reduce systemic portal pressure or treat the underlying liver disease.
- It does NOT substitute for hepatology care, beta-blocker therapy, endoscopic banding, or TIPS evaluation.
- It does NOT mean leech application is safe in patients with bleeding risk from liver disease — this is one of the highest-risk applications imaginable.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- gastrointestinal
- ICD-10
- K76.1, K76.6
- Safety tier
- high
Evidence Summary
Non-cirrhotic hepatic congestion (most commonly cardiac hepatopathy from right heart failure, or congestive hepatopathy from constrictive pericarditis) is managed by addressing the underlying cardiac pathology. No controlled clinical trial of leech therapy for non-cirrhotic hepatic congestion has been published; use is investigational and mechanistic only, and the honest evidence grade is D. Any local-decongestion rationale is plausible at most as a transient hemodynamic effect and is unproven. This entity is distinct from cirrhotic portal hypertension, which is an absolute contraindication given varices, coagulopathy, and infection risk.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Sotnikov OS et al. (2011)0
Detailed Trial Entries
4 trials indexed in the ASH RCT Library with full Study Profile, GRADE rating, and clinical implications:
- Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT)
Corbacioglu S, Bajwa R, Antmen AB, Balduzzi A, Boelens JJ, Bonifazi F, Cesaro S, Ciceri F, Colecchia A, Dignan F, Kleinschmidt K, Mahadeo KM, Pagliuca A, Sedlacek P, Shaw PJ, Stein J, Szmit Z, Tambaro F, Ince E, Verna M, Yesilipek A, Zecca M, Richardson PG, Mohty M, Kalwak K (2026) · Bone Marrow Transplantation · n=0 · GRADE moderate
- Burden of illness of non-hematopoietic stem cell transplant-related hepatic sinusoidal obstruction syndrome: A systematic review
Fan L, Stewart F, Ruiz K, Devani D, Fusco N, Gill M, Amber V, Su W, Gangi A, Hanvesakul R (2024) · Heliyon · n=0 · GRADE low
- Hepatic Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease (SOS/VOD) Primary Prophylaxis in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Network Meta-Analysis of Randomized Controlled Trials
Sousa-Pimenta M, Martins Â, Estevinho LM, Pinho Vaz C, Leite L, Mariz J (2024) · Journal of Clinical Medicine · n=0 · GRADE moderate
- Impact of Oral Eicosapentaenoic Acid on Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Onset Prevention: Single-Center Retrospective Analysis
Miyazaki Y, Narumi H, Azuma T, Tanimoto K, Masuda Y, Kato J, Konishi T, Nabe S, Maruta M, Ochi T, Yamanouchi J, Takenaka K (2025) · Transplantation and Cellular Therapy · n=138 · GRADE very-low
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Cirrhosis or portal hypertension (any cause)
- Esophageal/gastric varices
- Coagulopathy from hepatic dysfunction
- Decompensated heart failure
- Anticoagulation for cardiac indications
Related Conditions
Hemorrhoids (Grade II-III, Symptomatic)
Investigational use for symptomatic relief of grade II-III internal/external hemorrhoidal disease; does not address anatomic prolapse.
External Thrombosed Hemorrhoid (Acute, <72h)
Investigational adjunct for acute external thrombosed hemorrhoids presenting within 72 hours; distinct from internal hemorrhoidal disease.
Chronic Anal Fissure (>8 Weeks)
Investigational adjunct for chronic anal fissure refractory to medical therapy; very limited case-report evidence; surgical sphincterotomy remains gold standard.
Non-Alcoholic Fatty Liver Disease (Investigational Adjunct)
Investigational adjunct in NAFLD/MASLD; small case series only; weight loss, dietary modification, and resmetirom remain primary.